Rep. Waxman to revisit Rx drug pricing
The House Commerce/Health Subcommittee chairman is considering a second round of hearings on pharmaceutical industry price hikes. At a hearing last summer, the California Democrat criticized the industry for continued double-digit Rx drug price inflation, despite patent restoration and R&E tax credits, when general inflation was running below 4% ("The Pink Sheet" July 22, 1985, p. 5). If Waxman holds another hearing, he is expected to ask HHS Assistant Secretary for Planning & Evaluation Robert Helms to return as a witness. The chairman is reportedly concerned that after three years of review and comments on how to reform Rx drug reimbursement under Medicaid, HHS only recently published a proposal on MAC that included three disparate alternatives ("The Pink Sheet" Aug. 25, p. 3).
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.